Case number 2020-1074
Amgen Inc. v. Sanofi > Documents
| Date Field | Doc. No. | Description (Pages) |
|---|---|---|
| Jun 27, 2021 | 0 | AMGEN INC. v. SANOFI [ORDER] [nonprecedential] (0) |
| Apr 23, 2021 | 0 | AMGEN INC. v. SANOFI [OPINION] [precedential] (0) |
| Feb 11, 2021 | 132 | OPINION filed for the court by Prost, Chief Judge; Lourie, Circuit Judge and Hughes, Circuit Judge. Precedential Opinion. [755357] [JCP] [Entered: 02/11/2021 10:23 AM] (14) |
| Feb 11, 2021 | 133 | JUDGMENT. AFFIRMED. Terminated on the merits after oral argument. COSTS: Costs taxed against Appellant(s). Mandate to issue in due course. For information regarding costs, petitions for rehearing, and petitions for writs of certiorari click here. [755359] [JCP] [Entered: 02/11/2021 10:24 AM] (1) |
| Dec 9, 2020 | 131 | Submitted after ORAL ARGUMENT to Panel: Prost, Chief Judge; Lourie, Circuit Judge and Hughes, Circuit Judge.Arguing counsel: Jeffrey A. Lamken for Amgen USA, Inc., Amgen Inc. and Amgen Manufacturing, Limited and Matthew Wolf for Sanofi, Aventisub LLC, Regeneron Pharmaceuticals Inc. and Sanofi-Aventis U.S. LLC.Oral Argument Audio available here. [741378] [JAB] [Entered: 12/09/2020 11:16 AM] (0) |
| Nov 19, 2020 | 130 | Clerk's letter to Appellants Amgen Inc., Amgen Manufacturing, Limited, Amgen USA, Inc. and Appellees Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi and Sanofi-Aventis U.S. LLC regarding Telephonic Argument Orientation. Service as of this date by the Clerk of Court. [736900] [JAB] [Entered: 11/19/2020 11:45 AM] (0) |
| Nov 16, 2020 | 128 | Response to notice of oral argument from Appellees Sanofi, Sanofi-Aventis U.S. LLC, Regeneron Pharmaceuticals Inc. and Aventisub LLC. Service: 11/16/2020 by email. [735707] [20-1074] [Matthew Wolf] [Entered: 11/16/2020 11:40 AM] (1) |
| Nov 16, 2020 | 129 | Response to notice of oral argument from Appellants Amgen Inc., Amgen Manufacturing, Limited and Amgen USA, Inc.. Service: 11/16/2020 by email. [735819] [20-1074] [Jeffrey Lamken] [Entered: 11/16/2020 01:08 PM] (1) |
| Nov 10, 2020 | 127 | Notice of intent to use visual aids at oral argrument for Appellants Amgen Inc., Amgen Manufacturing, Limited and Amgen USA, Inc.. Service: 11/10/2020 by email. [734719] [20-1074] [Jeffrey Lamken] [Entered: 11/10/2020 10:53 AM] (7) |
| Oct 21, 2020 | 126 | NOTICE OF TELEPHONIC ORAL ARGUMENT. Panel: 2012G. Case scheduled December 9, 2020. Response to Notice of Oral Argument due: 11/16/2020. The Clerk's Office will provide additional instructions to counsel at least one week ahead of argument. Please review the attached Notice. The response to notice of oral argument form can be found here. The Oral Argument Guide can be found here. Service as of this date by the Clerk of Court. [730582] [JAB] [Entered: 10/21/2020 02:19 PM] (1) |
| Sep 1, 2020 | 124 | Supplementary Media Appendix received on CD-ROM from Amgen Inc., Amgen Manufacturing, Limited and Amgen USA, Inc. Number of copies: 4. [727946] [MJL] [Entered: 10/09/2020 03:22 PM] (0) |
| Aug 26, 2020 | 121 | 6 paper copies of the Confidential Joint Appendix in 3 Volumes [106] received from Appellants Amgen Inc., Amgen Manufacturing, Limited and Amgen USA, Inc. [723754]--[Edited 09/22/2020 by JCP to add confidential] [JCP] [Entered: 09/22/2020 05:01 PM] (0) |
| Aug 25, 2020 | 116 | The following conflict dates submitted by Jeffrey A. Lamken for Amgen USA, Inc., Amgen Inc. and Amgen Manufacturing, Limited have been accepted by the court: 12/07/2020. [717323] [JAB] [Entered: 08/25/2020 12:13 PM] (0) |
| Aug 25, 2020 | 117 | The following conflict dates submitted by Matthew Wolf for Sanofi, Aventisub LLC, Regeneron Pharmaceuticals Inc. and Sanofi-Aventis U.S. LLC have been accepted by the court: 11/02/2020, 11/03/2020, 11/04/2020, 11/05/2020, 11/06/2020. [717324] [JAB] [Entered: 08/25/2020 12:15 PM] (0) |
| Aug 25, 2020 | 120 | 6 paper copies of the Amicus Brief [102] received from Amicus Curiae Doctor Stanley D. Liang. [723753] [JCP] [Entered: 09/22/2020 04:59 PM] (0) |
| Aug 25, 2020 | 122 | 6 paper copies of the Confidential Reply Brief [104] received from Appellants Amgen Inc., Amgen Manufacturing, Limited and Amgen USA, Inc. [723756] [JCP] [Entered: 09/22/2020 05:02 PM] (0) |
| Aug 25, 2020 | 123 | 6 paper copies of the Opening Brief [55] received from Appellants Amgen Inc., Amgen Manufacturing, Limited and Amgen USA, Inc. [723758] [JCP] [Entered: 09/22/2020 05:05 PM] (0) |
| Aug 24, 2020 | 112 | Notice from Appellees Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S. LLC and Aventisub LLC regarding conflicts with oral argument. Service: 08/24/2020 by email. [716992] [20-1074] [Matthew Wolf] [Entered: 08/24/2020 02:14 PM] (2) |
| Aug 24, 2020 | 113 | The following conflict dates submitted by Matthew Wolf for Sanofi, Aventisub LLC, Regeneron Pharmaceuticals Inc. and Sanofi-Aventis U.S. LLC have been accepted by the court: 01/06/2021. [717004] [JAB] [Entered: 08/24/2020 02:23 PM] (0) |
| Aug 24, 2020 | 114 | Notice from Appellants Amgen Inc., Amgen Manufacturing, Limited and Amgen USA, Inc. regarding conflicts with oral argument. Service: 08/24/2020 by email. [717181] [20-1074] [Jeffrey Lamken] [Entered: 08/24/2020 07:41 PM] (3) |
| Aug 24, 2020 | 115 | Notice from Appellees Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi and Sanofi-Aventis U.S. LLC regarding conflicts with oral argument. Service: 08/24/2020 by email. [717192] [20-1074] [Matthew Wolf] [Entered: 08/24/2020 09:45 PM] (2) |
| Aug 24, 2020 | 125 | 6 paper copies of Doc. No. [75] received from Appellees Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi and Sanofi-Aventis U.S. LLC. [730310] [VDW] [Entered: 10/20/2020 03:46 PM] (0) |
| Aug 20, 2020 | 119 | 6 paper copies of Doc. No. [67] received from Bristol-Myers Squibb Company and Merck Sharp & Dohme Corp. [720119] [MJL] [Entered: 09/08/2020 01:50 PM] (0) |
| Aug 19, 2020 | 118 | 6 paper copies of Doc. No. [91] received from Pfizer Inc. [720036] [MJL] [Entered: 09/08/2020 11:44 AM] (0) |
| Aug 17, 2020 | 110 | Notice to counsel: The Clerk's Office directs that outstanding paper copies of all briefs and appendices in this case must be submitted on or before August 31, 2020. See Administrative Order No. 20-01 (Mar. 20, 2020). [715110] [JAL] [Entered: 08/17/2020 10:09 AM] (0) |
| Aug 17, 2020 | 111 | Notice to Advise of Scheduling Conflicts. Arguing counsel must advise of, and show good cause for, any scheduling conflicts during the upcoming court session months listed in the attached notice. The Response to Notice to Advise of Scheduling Conflicts can be found here. The Oral Argument Guide can be found here. [715111] [JAL] [Entered: 08/17/2020 10:10 AM] (1) |
| Jul 30, 2020 | 106 | MODIFIED ENTRY: CONFIDENTIAL APPENDIX FILED for Appellants Amgen Inc., Amgen Manufacturing, Limited, and Amgen USA, Inc. Number of Pages: 1301. Service: 07/30/2020 by email. [711461]--[Edited 08/03/2020 by JAL - Compliance review complete] [Sarah Newman] [Entered: 07/30/2020 08:40 PM] (0) |
| Jul 30, 2020 | 107 | MODIFIED ENTRY: APPENDIX FILED for Appellants Amgen Inc., Amgen Manufacturing, Limited, and Amgen USA, Inc. Number of Pages: 1304. Service: 07/30/2020 by email. [711462] --[Edited 08/03/2020 by JAL - Compliance review complete] [Sarah Newman] [Entered: 07/30/2020 08:49 PM] (1304) |
| Jul 30, 2020 | 108 | Certificate of Compliance with Fed. Cir. R. 25.1(c)(2) for Appellants Amgen Inc., Amgen Manufacturing, Limited, Amgen USA, Inc. and Appellees Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi and Sanofi-Aventis U.S. LLC. Service: 07/30/2020 by email. [711463] [20-1074] [Sarah Newman] [Entered: 07/30/2020 08:52 PM] (4) |
| Jul 30, 2020 | 109 | Joint Statement of Compliance with Fed. Cir. R. 33 for Appellants Amgen Inc., Amgen Manufacturing, Limited, Amgen USA, Inc. and Appellees Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi and Sanofi-Aventis U.S. LLC. Service: 07/30/2020 by email. [711464] [20-1074] [Sarah Newman] [Entered: 07/30/2020 08:54 PM] (4) |
| Jul 23, 2020 | 104 | MODIFIED ENTRY: CONFIDENTIAL REPLY BRIEF FILED for Appellants Amgen Inc., Amgen Manufacturing, Limited, and Amgen USA, Inc. Number of Pages: 35. Service: 07/23/2020 by email. [709794]--[Edited 07/29/2020 by JAL - Compliance review complete] [Jeffrey Lamken] [Entered: 07/23/2020 08:30 PM] (0) |
| Jul 23, 2020 | 105 | MODIFIED ENTRY: REPLY BRIEF FILED for Appellants Amgen Inc., Amgen Manufacturing, Limited, and Amgen USA, Inc. Number of Pages: 35. Service: 07/23/2020 by email. Unless ordered otherwise, any responsive deadline runs from the date of service of this brief. See Fed. Cir. R. 31. [709795] --[Edited 07/29/2020 by JAL - Compliance review complete] [Jeffrey Lamken] [Entered: 07/23/2020 08:33 PM] (51) |
| Jul 2, 2020 | 101 | ORDER filed granting [95] the motion. A copy of this order and the motion papers shall be forwarded to the merits panel assigned to this case. Service as of this date by the Clerk of Court. [705172] [LMS] [Entered: 07/02/2020 12:17 PM] (2) |
| Jul 2, 2020 | 102 | AMICUS BRIEF FILED for Amicus Curiae Doctor Stanley D. Liang. Pages: 32. Service: 07/02/2020 by clerk. [705175] [Accepted pursuant to 07/02/2020 order [705102-2]] [JAL] [Entered: 07/02/2020 12:28 PM] (41) |
| Jul 2, 2020 | 103 | Entry of appearance for Stanley D. Liang as counsel for Amicus Curiae Doctor Stanley D. Liang. Service: 07/02/2020 by clerk. [705178] [JAL] [Entered: 07/02/2020 12:29 PM] (2) |
| Jun 23, 2020 | 100 | MODIFIED ENTRY: REPLY of Stanley Liang to response [99]. Service: 06/23/2020 by email. [703174]--[Edited 06/24/2020 by JAL - Reason: to correct filing event] [Stanley Liang] [Entered: 06/23/2020 05:55 PM] (5) |
| Jun 19, 2020 | 99 | RESPONSE of Appellants Amgen Inc., Amgen Manufacturing, Limited and Amgen USA, Inc. to the motion [95]. Service: 06/19/2020 by email. [702568] [20-1074] [Jeffrey Lamken] [Entered: 06/19/2020 04:04 PM] (30) |
| Jun 17, 2020 | 98 | ORDER filed. Any opposition to the motion [95] shall be filed no later than seven days from the date of issuance of this order. Any reply is due no later than three days from the filing of any response. Service as of this date by the Clerk of Court. [701785] [NL] [Entered: 06/17/2020 10:13 AM] (2) |
| Jun 16, 2020 | 97 | **TEXT ONLY** ORDER granting motion to extend time to file brief [96] filed by Appellants Amgen USA, Inc., Amgen Inc., and Amgen Manufacturing, Limited. The reply brief is due 07/23/2020. Service as of this date by the Clerk of Court. This order has been issued without an attached document and is official and binding. [701464] [JAL] [Entered: 06/16/2020 11:17 AM] (0) |
| Jun 15, 2020 | 96 | MOTION of Appellants Amgen Inc., Amgen Manufacturing, Limited and Amgen USA, Inc. to extend the time to 07/23/2020 to file the Reply Brief. [Consent: unopposed]. Service: 06/15/2020 by email. [701328] [20-1074] [Jeffrey Lamken] [Entered: 06/15/2020 08:59 PM] (15) |
| Jun 12, 2020 | 95 | MODIFIED ENTRY: MOTION of Stanley D. Liang for leave to file an amicus curiae brief [Consent: opposed]. Service: 06/12/2020 by email. [700902]--[Edited 06/16/2020 by JAL - Reason: to correct filing event] [Stanley Liang] [Entered: 06/12/2020 04:58 PM] (49) |
| Jun 9, 2020 | 93 | Notice to counsel for Amicus Curiae Pfizer Inc.: The record of this case indicates that the Certificate of Interest has not been separately filed from the brief. Please file the document promptly. Service as of this date by the Clerk of Court. [700090] [JAL] [Entered: 06/09/2020 01:21 PM] (0) |
| Jun 9, 2020 | 94 | Certificate of Interest for Amicus Curiae Pfizer Inc.. Service: 06/09/2020 by email. [700100] [20-1074] [Amit Thakore] [Entered: 06/09/2020 01:57 PM] (2) |
| Jun 8, 2020 | 85 | NOTICE OF NON-COMPLIANCE: The submission of Amicus Curiae Eli Lilly and Company, Amicus Brief [84], is not in compliance with the rules of this court (see attached). Compliant document is due on 06/15/2020. Service as of this date by the Clerk of Court. [699777] [JAL] [Entered: 06/08/2020 10:44 AM] (1) |
| Jun 8, 2020 | 86 | NOTICE OF NON-COMPLIANCE: The submissions of Stanley D. Liang, Amicus Brief and Entry of Appearance - S. Liang [81], [82], are not in compliance with the rules of this court (see attached). Compliant documents are due on 06/15/2020. Service as of this date by the Clerk of Court. [699780] [JAL] [Entered: 06/08/2020 10:54 AM] (2) |
| Jun 8, 2020 | 87 | Entry of appearance for Amit H. Thakore as principal counsel for Amicus Curiae Pfizer Inc.. Service: 06/08/2020 by email. [699906] [20-1074] [Amit Thakore] [Entered: 06/08/2020 04:08 PM] (2) |
| Jun 8, 2020 | 88 | Entry of appearance for Elizabeth Chang as of counsel for Amicus Curiae Pfizer Inc.. Service: 06/08/2020 by email. [699908] [20-1074] [Amit Thakore] [Entered: 06/08/2020 04:10 PM] (2) |
| Jun 8, 2020 | 89 | Entry of appearance for Dimitrios Drivas as of counsel for Amicus Curiae Pfizer Inc.. Service: 06/08/2020 by email. [699909] [20-1074] [Amit Thakore] [Entered: 06/08/2020 04:12 PM] (2) |
| Jun 8, 2020 | 90 | Entry of appearance for Jeffrey N. Myers as of counsel for Amicus Curiae Pfizer Inc.. Service: 06/08/2020 by email. [699910] [20-1074] [Amit Thakore] [Entered: 06/08/2020 04:15 PM] (2) |
| Jun 8, 2020 | 91 | MODIFIED ENTRY: AMICUS BRIEF FILED for Amicus Curiae Pfizer Inc. Pages: 26. Service: 06/08/2020 by email. [699914]--[Edited 06/09/2020 by JAL - Compliance review complete] [Amit Thakore] [Entered: 06/08/2020 04:21 PM] (36) |
| Jun 8, 2020 | 92 | MODIFIED ENTRY: CORRECTED AMICUS BRIEF FILED for Amicus Curiae Eli Lilly and Company. Pages: 27. Service: 06/08/2020 by email. [699930]--[Edited 06/09/2020 by JAL - Compliance review complete] [Duane Marks] [Entered: 06/08/2020 04:59 PM] (36) |
| Jun 5, 2020 | 77 | Entry of appearance for Duane C. Marks as principal counsel for Eli Lilly and Company. Service: 06/05/2020 by email. [699431] [20-1074] [Duane Marks] [Entered: 06/05/2020 09:44 AM] (2) |
| Jun 5, 2020 | 78 | Certificate of Interest for Eli Lilly and Company. Service: 06/05/2020 by email. [699436] [20-1074] [Duane Marks] [Entered: 06/05/2020 09:48 AM] (2) |
| Jun 5, 2020 | 79 | Entry of appearance for Gilbert Voy as of counsel for Eli Lilly and Company. Service: 06/05/2020 by email. [699442] [20-1074] [Gilbert Voy] [Entered: 06/05/2020 09:57 AM] (2) |
| Jun 5, 2020 | 80 | Entry of appearance for Mark Stewart as of counsel for Eli Lilly and Company. Service: 06/05/2020 by email. [699445] [20-1074] [Mark Stewart] [Entered: 06/05/2020 10:12 AM] (2) |
| Jun 5, 2020 | 81 | FILED from Stanley D Liang. Title: AMICUS CURIAE BRIEF. Service: 06/05/2020 by email. [699547] [20-1074] This document is non-compliant. See Doc. No.[86] [Stanley Liang] [Entered: 06/05/2020 12:24 PM] (39) |
| Jun 5, 2020 | 82 | Entry of appearance for Stanley D Liang as principal counsel for Stanley D Liang. Service: 05/05/2020 by email. [699550] [20-1074] This document is non-compliant. See Doc. No.[86] [Stanley Liang] [Entered: 06/05/2020 12:27 PM] (1) |
| Jun 5, 2020 | 83 | Entry of appearance for Tonya L. Combs as of counsel for Eli Lilly and Company. Service: 06/05/2020 by email. [699618] [20-1074] [Tonya Combs] [Entered: 06/05/2020 02:22 PM] (2) |
| Jun 5, 2020 | 84 | FILED from Eli Lilly and Company Title: AMICUS CURIAE BRIEF. Service: 06/05/2020 by email. [699622] [20-1074] This document is non-compliant. See Doc. No.[85] [Duane Marks] [Entered: 06/05/2020 02:26 PM] (36) |
| Jun 2, 2020 | 74 | NOTICE OF NON-COMPLIANCE: The submissions of Appellees Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, and Sanofi-Aventis U.S. LLC, Response Brief (Confidential and Non-Confidential) [72], [73], are not in compliance with the rules of this court (see attached). Compliant documents are due on 06/09/2020. Service as of this date by the Clerk of Court. [698595] [JAL] [Entered: 06/02/2020 11:43 AM] (1) |
| Jun 2, 2020 | 75 | MODIFIED ENTRY: CORRECTED CONFIDENTIAL RESPONSE BRIEF FILED for Appellees Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, and Sanofi-Aventis U.S. LLC. Number of Pages: 63. Service: 06/02/2020 by email. [698782]--[Edited 06/03/2020 by JAL - Compliance review complete] [Calvin Shank] [Entered: 06/02/2020 09:31 PM] (0) |
| Jun 2, 2020 | 76 | MODIFIED ENTRY: CORRECTED RESPONSE BRIEF FILED for Appellees Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, and Sanofi-Aventis U.S. LLC. Number of Pages: 63. Service: 06/02/2020 by email. Unless ordered otherwise, any responsive deadline runs from the date of service of this brief. See Fed. Cir. R. 31. [698784] --[Edited 06/03/2020 by JAL - Compliance review complete] [Calvin Shank] [Entered: 06/02/2020 09:39 PM] (76) |
| Jun 1, 2020 | 70 | Amended Certificate of Interest for Appellees Sanofi, Aventisub LLC, Regeneron Pharmaceuticals Inc. and Sanofi-Aventis U.S. LLC. Service: 06/01/2020 by email. [698114] [20-1074] [Calvin Shank] [Entered: 06/01/2020 10:13 AM] (3) |
| Jun 1, 2020 | 71 | Amended Certificate of Interest for Appellees Sanofi, Aventisub LLC, Regeneron Pharmaceuticals Inc. and Sanofi-Aventis U.S. LLC. Service: 06/01/2020 by email. [698412] [20-1074] [Calvin Shank] [Entered: 06/01/2020 07:07 PM] (3) |
| Jun 1, 2020 | 72 | FILED from Appellees Sanofi, Aventisub LLC, Regeneron Pharmaceuticals Inc. and Sanofi-Aventis U.S. LLC. Title: CONFIDENTIAL RESPONSE BRIEF. Service: 06/01/2020 by email. [698413] [20-1074] This document is non-compliant. See Doc. No.[74] [Calvin Shank] [Entered: 06/01/2020 07:14 PM] (0) |
| Jun 1, 2020 | 73 | FILED from Appellees Sanofi, Aventisub LLC, Regeneron Pharmaceuticals Inc. and Sanofi-Aventis U.S. LLC. Title: RESPONSE BRIEF. Service: 06/01/2020 by email. [698415] [20-1074] This document is non-compliant. See Doc. No.[74] [Calvin Shank] [Entered: 06/01/2020 07:26 PM] (76) |
| May 29, 2020 | 69 | **TEXT ONLY** ORDER granting motion to withdraw Katherine Nicole Clouse as counsel [68] filed by Appellants Amgen USA, Inc., Amgen Inc., and Amgen Manufacturing, Limited. Service as of this date by the Clerk of Court. This order has been issued without an attached document and is official and binding. [697752] [JAL] [Entered: 05/29/2020 09:09 AM] (0) |
| May 28, 2020 | 68 | MOTION of Appellants Amgen Inc., Amgen Manufacturing, Limited and Amgen USA, Inc. to withdraw counsel Katherine Nicole Clouse [Consent: unopposed]. Service: 05/28/2020 by clerk, email. [697666] [20-1074] [William Gaede] [Entered: 05/28/2020 05:55 PM] (7) |
| Mar 25, 2020 | 66 | ORDER filed granting motion for leave to file an amicus curiae brief [61]. The brief is accepted for filing.. Service as of this date by the Clerk of Court. [681640] [NL] [Entered: 03/25/2020 12:27 PM] (2) |
| Mar 25, 2020 | 67 | AMICUS BRIEF FILED for Amici Curiae Bristol-Myers Squibb Company and Merck Sharp & Dohme Corp. Pages: 23. Service: 02/28/2020 by email. [681657] [Accepted pursuant to order [66]] [JAL] [Entered: 03/25/2020 12:58 PM] (32) |
| Mar 10, 2020 | 65 | ORDER granting motion to extend time to file brief [64] filed by Appellees. The response brief is due 06/01/2020. Service as of this date by the Clerk of Court. [677592] [NL] [Entered: 03/10/2020 02:26 PM] (2) |
| Mar 5, 2020 | 64 | MOTION of Appellees Sanofi, Aventisub LLC, Regeneron Pharmaceuticals Inc. and Sanofi-Aventis U.S. LLC to extend the time to 06/01/2020 to file Response/Reply [Consent: unopposed]. Service: 03/05/2020 by email. [676760] [20-1074] [Matthew Wolf] [Entered: 03/05/2020 06:53 PM] (10) |
| Feb 28, 2020 | 58 | Entry of appearance for Jorge A. Goldstein as principal counsel for Bristol-Myers Squibb Co. and Merck Sharp & Dohme Corp.. Service: 02/28/2020 by email. [675341] [20-1074] [Kristina Caggiano Kelly] [Entered: 02/28/2020 06:29 PM] (2) |
| Feb 28, 2020 | 59 | Entry of appearance for Kristina Caggiano Kelly as of counsel for Bristol-Myers Squibb Co. and Merck Sharp & Dohme Corp.. Service: 02/28/2020 by email. [675343] [20-1074] [Kristina Caggiano Kelly] [Entered: 02/28/2020 06:31 PM] (2) |
| Feb 28, 2020 | 60 | Certificate of Interest for Bristol-Myers Squibb Co. and Merck Sharp & Dohme Corp.. Service: 02/28/2020 by email. [675344] [20-1074] [Kristina Caggiano Kelly] [Entered: 02/28/2020 06:34 PM] (3) |
| Feb 28, 2020 | 61 | MOTION of Bristol-Myers Squibb Co. and Merck Sharp & Dohme Corp. for leave to file an amicus curiae brief [Consent: unopposed]. Service: 02/28/2020 by email. [675345] [20-1074] [Kristina Caggiano Kelly] [Entered: 02/28/2020 06:38 PM] (41) |
| Feb 28, 2020 | 62 | Entry of appearance for Eldora L. Ellison as of counsel for Bristol-Myers Squibb Co. and Merck Sharp & Dohme Corp.. Service: 02/28/2020 by email. [675346] [20-1074] [Eldora Ellison] [Entered: 02/28/2020 06:41 PM] (2) |
| Feb 28, 2020 | 63 | Entry of appearance for William H. Milliken as of counsel for Bristol-Myers Squibb Co. and Merck Sharp & Dohme Corp.. Service: 02/28/2020 by email. [675347] [20-1074] [William Milliken] [Entered: 02/28/2020 06:43 PM] (2) |
| Feb 27, 2020 | 57 | Amended Entry of appearance for Victoria Reines as of counsel for Appellees Sanofi, Sanofi-Aventis U.S. LLC, Aventisub LLC and Regeneron Pharmaceuticals Inc.. Service: 02/27/2020 by email. [674772] [20-1074] [Victoria Reines] [Entered: 02/27/2020 12:15 PM] (3) |
| Feb 25, 2020 | 56 | REMINDER: All counsel of record are reminded of their responsibility per Fed. Cir. R. 47.3 to promptly submit an amended Entry of Appearance and/or update their contact information via PACER as information changes during the pendency of the appeal. Failure to comply with these Rules may delay the timely processing of your case or result in adverse action. [674067] [JAL] [Entered: 02/25/2020 02:29 PM] (0) |
| Feb 21, 2020 | 46 | Entry of appearance for Wendy A. Whiteford as of counsel for Appellants Amgen Inc., Amgen Manufacturing Limited and Amgen USA, Inc.. Service: 02/21/2020 by email. [673303] [20-1074] [Wendy Whiteford] [Entered: 02/21/2020 02:34 PM] (2) |
| Feb 21, 2020 | 47 | Entry of appearance for Erica Olson as principal counsel for Appellants Amgen Inc., Amgen Manufacturing Limited, Amgen Manufacturing, Limited and Amgen USA, Inc.. Service: 02/21/2020 by email. [673309] [20-1074] [Erica Olson] [Entered: 02/21/2020 02:38 PM] (2) |
| Feb 21, 2020 | 48 | Corrected Entry of appearance for Erica Olson as of counsel for Appellants Amgen Inc., Amgen Manufacturing Limited, Amgen Manufacturing, Limited and Amgen USA, Inc.. Service: 02/21/2020 by email. [673356] [20-1074] [Erica Olson] [Entered: 02/21/2020 03:31 PM] (2) |
| Feb 21, 2020 | 49 | Entry of appearance for Stuart Watt as of counsel for Appellants Amgen Inc., Amgen Manufacturing Limited, Amgen Manufacturing, Limited and Amgen USA, Inc.. Service: 02/21/2020 by email. [673358] [20-1074] [Stuart Watt] [Entered: 02/21/2020 03:38 PM] (2) |
| Feb 21, 2020 | 50 | Entry of appearance for Emily Curtis Johnson as of counsel for Appellants Amgen Inc., Amgen Manufacturing Limited, Amgen Manufacturing, Limited and Amgen USA, Inc.. Service: 02/21/2020 by email. [673402] [20-1074] [Emily Johnson] [Entered: 02/21/2020 04:44 PM] (2) |
| Feb 21, 2020 | 51 | Entry of appearance for Steven D. Tang as of counsel for Appellants Amgen Inc., Amgen Manufacturing Limited, Amgen Manufacturing, Limited and Amgen USA, Inc.. Service: 02/21/2020 by email. [673418] [20-1074] [Steven Tang] [Entered: 02/21/2020 05:13 PM] (2) |
| Feb 21, 2020 | 52 | Amended Entry of appearance for Sarah J. Newman as of counsel for Appellants Amgen Inc., Amgen Manufacturing, Limited and Amgen USA, Inc.. Service: 02/21/2020 by email. [673455] [20-1074] [Sarah Newman] [Entered: 02/21/2020 07:15 PM] (2) |
| Feb 21, 2020 | 53 | Amended Entry of appearance for Michael G. Pattillo, Jr. as of counsel for Appellants Amgen Inc., Amgen Manufacturing, Limited and Amgen USA, Inc.. Service: 02/21/2020 by email. [673456] [20-1074] [Michael Pattillo] [Entered: 02/21/2020 07:18 PM] (2) |
| Feb 21, 2020 | 54 | Amended Entry of appearance for Jeffrey A. Lamken as principal counsel for Appellants Amgen Inc., Amgen Manufacturing, Limited and Amgen USA, Inc.. Service: 02/21/2020 by email. [673457] [20-1074] [Jeffrey Lamken] [Entered: 02/21/2020 07:21 PM] (2) |
| Feb 21, 2020 | 55 | MODIFIED ENTRY: OPENING BRIEF FILED for Appellants Amgen Inc., Amgen Manufacturing, Limited, and Amgen USA, Inc. Number of Pages: 69. Service: 02/21/2020 by email. Unless ordered otherwise, any responsive deadline runs from the date of service of this brief. See Fed. Cir. R. 31. [673458] --[Edited 02/25/2020 by JAL - Compliance review complete] [Jeffrey Lamken] [Entered: 02/21/2020 07:26 PM] (124) |
| Feb 7, 2020 | 45 | ORDER granting motion to withdraw Anne W. Pearlman as counsel [44] filed by Appellees Sanofi, Aventisub LLC, Regeneron Pharmaceuticals Inc., and Sanofi-Aventis U.S. LLC. Service as of this date by the Clerk of Court. [669246] [JAL] [Entered: 02/07/2020 09:38 AM] (2) |
| Feb 5, 2020 | 44 | MOTION of Appellees Sanofi, Aventisub LLC, Regeneron Pharmaceuticals Inc. and Sanofi-Aventis U.S. LLC to withdraw counsel Anne W. Pearlman [Consent: not addressed]. Service: 02/05/2020 by email. [668683] [20-1074] [Anne Pearlman] [Entered: 02/05/2020 02:19 PM] (6) |
| Jan 16, 2020 | 43 | Entry of appearance for Lauren Martin as of counsel for Appellant Amgen Inc.. Service: 01/16/2020 by email, US mail. [663717] [20-1074] [Lauren Martin] [Entered: 01/16/2020 10:19 AM] (2) |
| Jan 15, 2020 | 42 | **TEXT ONLY** ORDER granting motion to extend time to file brief [41] filed by Appellants Amgen USA, Inc., Amgen Inc., and Amgen Manufacturing, Limited. The opening brief is due 02/21/2020. Service as of this date by the Clerk of Court. This order has been issued without an attached document and is official and binding. [663096] [JAL] [Entered: 01/15/2020 09:33 AM] (0) |
| Jan 14, 2020 | 40 | Amended Certificate of Interest for Appellants Amgen Inc., Amgen Manufacturing, Limited and Amgen USA, Inc.. Service: 01/14/2020 by email. [662977] [20-1074] [Jeffrey Lamken] [Entered: 01/14/2020 04:41 PM] (5) |
| Jan 14, 2020 | 41 | MOTION of Appellants Amgen Inc., Amgen Manufacturing, Limited and Amgen USA, Inc. to extend the time to 02/21/2020 to file the Opening Brief. [Consent: unopposed]. Service: 01/14/2020 by email. [662979] [20-1074] [Jeffrey Lamken] [Entered: 01/14/2020 04:45 PM] (14) |
| Dec 23, 2019 | 39 | Corrected Entry of appearance for Christopher B. Mead as principal counsel for Appellants Amgen Inc., Amgen Manufacturing Limited and Amgen USA, Inc.. Service: 12/23/2019 by email. [658512] [20-1074] [Christopher Mead] [Entered: 12/23/2019 02:07 PM] (2) |
| Dec 16, 2019 | 38 | **TEXT ONLY** ORDER granting motion to extend time to file brief [37] filed by Appellants Amgen USA, Inc., Amgen Inc., and Amgen Manufacturing, Limited. The opening brief is due 01/22/2020. Service as of this date by the Clerk of Court. This order has been issued without an attached document and is official and binding. [656657] [JAL] [Entered: 12/16/2019 09:16 AM] (0) |
| Dec 13, 2019 | 37 | MOTION of Appellants Amgen Inc., Amgen Manufacturing, Limited and Amgen USA, Inc. to extend the time to 01/22/2020 to file the Opening Brief. [Consent: unopposed]. Service: 12/13/2019 by email. [656581] [20-1074] [Jeffrey Lamken] [Entered: 12/13/2019 04:41 PM] (14) |
| Dec 11, 2019 | 36 | Notice to counsel for Appellants Amgen Inc., Amgen Manufacturing, Limited, and Amgen USA, Inc.: The record of this case indicates that the Corrected Entry of Appearance for C. Mead has not been filed. Service as of this date by the Clerk of Court. [655710] [JAL] [Entered: 12/11/2019 03:02 PM] (0) |
| Nov 18, 2019 | 35 | Official caption revised in response to Notice of Objection to the Official Caption [5]. The official caption is reflected on the electronic docket under the listing of the parties and counsel. Service as of this date by the Clerk of Court. [649867] [JAL] [Entered: 11/18/2019 09:05 AM] (0) |
| Nov 14, 2019 | 28 | NOTICE OF NON-COMPLIANCE: The submission of Amgen Inc., Amgen Manufacturing Limited, and Amgen USA, Inc., Entry of Appearance - W. Gaede III [27], is not in compliance with the rules of this court (see attached). Compliant document due 11/21/2019. Service as of this date by the Clerk of Court. [649092]--[Edited 11/14/2019 by MJL to correct filed date] [JAL] [Entered: 11/13/2019 04:38 PM] (1) |
| Nov 14, 2019 | 29 | Entry of appearance for Sarah Chapin Columbia as of counsel for Appellant Amgen Inc.. Service: 11/14/2019 by clerk, email. [649291] [20-1074] [Sarah Columbia] [Entered: 11/14/2019 12:58 PM] (2) |
| Nov 14, 2019 | 30 | Entry of appearance for Katherine Nicole Clouse as of counsel for Appellant Amgen Inc.. Service: 11/14/2019 by clerk, email. [649293] [20-1074] [Sarah Columbia] [Entered: 11/14/2019 01:00 PM] (2) |
| Nov 14, 2019 | 31 | Entry of appearance for Katherine Nicole Clouse as of counsel for Appellant Amgen Inc.. Service: 11/14/2019 by clerk, email. [649296] [20-1074] [Katherine Clouse] [Entered: 11/14/2019 01:09 PM] (2) |
| Nov 14, 2019 | 32 | Corrected Entry of appearance for William G. Gaede III as of counsel for Appellants Amgen Inc., Amgen Manufacturing Limited and Amgen USA, Inc.. Service: 11/14/2019 by clerk, email. [649316] [20-1074] [William Gaede] [Entered: 11/14/2019 01:32 PM] (2) |
| Nov 14, 2019 | 33 | Entry of appearance for Christopher B. Mead as of counsel for. Service: 11/14/2019 by email. [649322] [20-1074] This document is non-compliant. See Doc No.[34] [Christopher Mead] [Entered: 11/14/2019 01:43 PM] (1) |
| Nov 14, 2019 | 34 | NOTICE OF NON-COMPLIANCE: The submission of Appellants Amgen Inc., Amgen Manufacturing Limited, and Amgen USA, Inc., Entry of Appearance - C. Mead [33], is not in compliance with the rules of this court (see attached). Compliant document is due on 11/21/2019. Service as of this date by the Clerk of Court. [649464] [JAL] [Entered: 11/14/2019 04:18 PM] (2) |
| Nov 11, 2019 | 27 | Entry of appearance for William G. Gaede, III as of counsel for Appellants Amgen Inc., Amgen Manufacturing Limited and Amgen USA, Inc. Service: 11/11/2019 by clerk, email. [648411] [20-1074] This document is non-compliant. See Doc No.[28] [William Gaede] [Entered: 11/11/2019 12:11 PM] (2) |
| Nov 8, 2019 | 25 | REMINDER: All counsel of record are reminded of their responsibility per Fed. Cir. R. 47.3 to promptly submit an amended Entry of Appearance and/or update their contact information through the PACER Service Center as information changes during the pendency of the appeal. Failure to comply with these Rules may delay the timely processing of your case or result in adverse action. [648262]--[Edited 11/08/2019 by JAL to amend docket text] [JAL] [Entered: 11/08/2019 03:15 PM] (0) |
| Nov 8, 2019 | 26 | Entry of appearance for Keith R. Hummel as of counsel for Appellants Amgen Inc., Amgen Manufacturing Limited and Amgen USA, Inc.. Service: 11/08/2019 by email. [648368] [20-1074] [Keith Hummel] [Entered: 11/08/2019 05:01 PM] (2) |
| Nov 7, 2019 | 2 | Entry of appearance for Jeffrey A. Lamken as principal counsel for Appellants Amgen Inc., Amgen Manufacturing Limited and Amgen USA, Inc.. Service: 11/07/2019 by email. [647778] [20-1074] [Jeffrey Lamken] [Entered: 11/07/2019 02:03 PM] (2) |
| Nov 7, 2019 | 3 | Certificate of Interest for Appellants Amgen Inc., Amgen Manufacturing Limited and Amgen USA, Inc.. Service: 11/07/2019 by email. [647779] [20-1074] [Jeffrey Lamken] [Entered: 11/07/2019 02:05 PM] (5) |
| Nov 7, 2019 | 4 | Docketing Statement for the Appellants Amgen Inc., Amgen Manufacturing Limited and Amgen USA, Inc.. Service: 11/07/2019 by email. [647781] [20-1074] [Jeffrey Lamken] [Entered: 11/07/2019 02:06 PM] (4) |
| Nov 7, 2019 | 5 | Objection to the official caption pursuant to Rule 12 Practice Note by Appellants Amgen Inc., Amgen Manufacturing Limited and Amgen USA, Inc.. Service: 11/07/2019 by email. [647785] [20-1074] [Jeffrey Lamken] [Entered: 11/07/2019 02:08 PM] (3) |
| Nov 7, 2019 | 6 | Entry of appearance for Michael G. Pattillo, Jr. as of counsel for Appellants Amgen Inc., Amgen Manufacturing Limited and Amgen USA, Inc.. Service: 11/07/2019 by email. [647789] [20-1074] [Michael Pattillo] [Entered: 11/07/2019 02:10 PM] (2) |
| Nov 7, 2019 | 7 | Entry of appearance for Sarah J. Newman as of counsel for Appellants Amgen Inc., Amgen Manufacturing Limited and Amgen USA, Inc.. Service: 11/07/2019 by email. [647791] [20-1074] [Sarah Newman] [Entered: 11/07/2019 02:14 PM] (2) |
| Nov 7, 2019 | 8 | Entry of appearance for Sara E. Margolis as of counsel for Appellants Amgen Inc., Amgen Manufacturing Limited and Amgen USA, Inc.. Service: 11/07/2019 by email. [647797] [20-1074] [Sara Margolis] [Entered: 11/07/2019 02:19 PM] (2) |
| Nov 7, 2019 | 9 | Entry of appearance for George W. Hicks as of counsel for Appellees Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi and Sanofi-Aventis U.S. LLC. Service: 11/07/2019 by email. [647833] [20-1074] [Calvin Shank] [Entered: 11/07/2019 03:14 PM] (2) |
| Nov 7, 2019 | 10 | Entry of appearance for Nathan S. Mammen as of counsel for Appellees Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi and Sanofi-Aventis U.S. LLC. Service: 11/07/2019 by email. [647834] [20-1074] [Calvin Shank] [Entered: 11/07/2019 03:15 PM] (2) |
| Nov 7, 2019 | 11 | Entry of appearance for C. Alex Shank as of counsel for Appellees Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi and Sanofi-Aventis U.S. LLC. Service: 11/07/2019 by email. [647836] [20-1074] [Calvin Shank] [Entered: 11/07/2019 03:16 PM] (2) |
| Nov 7, 2019 | 12 | Docketing Statement for the Appellees Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi and Sanofi-Aventis U.S. LLC. Service: 11/07/2019 by email. [647838] [20-1074] [Calvin Shank] [Entered: 11/07/2019 03:18 PM] (3) |
| Nov 7, 2019 | 13 | Certificate of Interest for Appellees Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi and Sanofi-Aventis U.S. LLC. Service: 11/07/2019 by email. [647840] [20-1074] [Calvin Shank] [Entered: 11/07/2019 03:19 PM] (3) |
| Nov 7, 2019 | 14 | Entry of appearance for Matthew W. Wolf as principal counsel for Appellees Sanofi, Sanofi-Aventis U.S. LLC, Aventisub LLC and Regeneron Pharmaceuticals Inc.. Service: 11/07/2019 by email. [647871] [20-1074] [Matthew Wolf] [Entered: 11/07/2019 04:05 PM] (3) |
| Nov 7, 2019 | 15 | Entry of appearance for Melanie K. Sharp as of counsel for Appellants Amgen Inc., Amgen Manufacturing Limited and Amgen USA, Inc.. Service: 11/07/2019 by email. [647876] [20-1074] [Melanie Sharp] [Entered: 11/07/2019 04:14 PM] (2) |
| Nov 7, 2019 | 16 | Entry of appearance for Larry Coury as of counsel for Appellee Regeneron Pharmaceuticals Inc.. Service: 11/07/2019 by email. [647886] [20-1074] [Anne Pearlman] [Entered: 11/07/2019 04:22 PM] (3) |
| Nov 7, 2019 | 17 | Entry of appearance for James L. Higgins as of counsel for Appellants Amgen Inc., Amgen Manufacturing Limited and Amgen USA, Inc.. Service: 11/07/2019 by email. [647889] [20-1074] [James Higgins] [Entered: 11/07/2019 04:23 PM] (2) |
| Nov 7, 2019 | 18 | Entry of appearance for Lynda Q. Nguyen as of counsel for Appellee Regeneron Pharmaceuticals Inc.. Service: 11/07/2019 by email. [647893] [20-1074] [Anne Pearlman] [Entered: 11/07/2019 04:25 PM] (3) |
| Nov 7, 2019 | 19 | Entry of appearance for Stephanie Donahue as of counsel for Appellees Sanofi, Sanofi-Aventis U.S. LLC and Aventisub LLC. Service: 11/07/2019 by email. [647898] [20-1074] [Anne Pearlman] [Entered: 11/07/2019 04:28 PM] (3) |
| Nov 7, 2019 | 20 | Entry of appearance for Anne Pearlman as of counsel for Appellees Sanofi, Sanofi-Aventis U.S. LLC, Aventisub LLC and Regeneron Pharmaceuticals Inc.. Service: 11/07/2019 by email. [647903] [20-1074] [Anne Pearlman] [Entered: 11/07/2019 04:32 PM] (3) |
| Nov 7, 2019 | 21 | Entry of appearance for Daniel L. Reisner as of counsel for Appellees Sanofi, Sanofi-Aventis U.S. LLC, Aventisub LLC and Regeneron Pharmaceuticals Inc.. Service: 11/07/2019 by email. [647907] [20-1074] [Daniel Reisner] [Entered: 11/07/2019 04:37 PM] (3) |
| Nov 7, 2019 | 22 | Entry of appearance for David K. Barr as of counsel for Appellees Sanofi, Sanofi-Aventis U.S. LLC, Aventisub LLC and Regeneron Pharmaceuticals Inc.. Service: 11/07/2019 by email. [647913] [20-1074] [David Barr] [Entered: 11/07/2019 04:41 PM] (3) |
| Nov 7, 2019 | 23 | Entry of appearance for Deborah Fishman as of counsel for Appellees Sanofi, Sanofi-Aventis U.S. LLC, Aventisub LLC and Regeneron Pharmaceuticals Inc.. Service: 11/07/2019 by email. [647919] [20-1074] [Deborah Fishman] [Entered: 11/07/2019 04:47 PM] (3) |
| Nov 7, 2019 | 24 | Entry of appearance for Victoria Reines as of counsel for Appellees Sanofi, Sanofi-Aventis U.S. LLC, Aventisub LLC and Regeneron Pharmaceuticals Inc.. Service: 11/07/2019 by email. [647920] [20-1074] [Victoria Reines] [Entered: 11/07/2019 04:51 PM] (3) |
| Oct 24, 2019 | 1 | Appeal docketed. Received: 10/23/2019. [644354]Entry of Appearance is due 11/07/2019. Certificate of Interest is due on 11/07/2019. Docketing Statement is due 11/07/2019. Appellant's brief is due 12/23/2019. [JAL] [Entered: 10/24/2019 10:10 AM] (100) |
